Workflow
SHANGHAI KAIBAO(300039)
icon
Search documents
上海凯宝:独立董事提名人声明与承诺(三)
2023-12-05 11:11
上海凯宝药业股份有限公司 独立董事提名人声明与承诺 提名人上海凯宝药业股份有限公司董事会现就提名李清伟先生为上海凯宝药业股 份有限公司第六届董事会独立董事候选人发表公开声明。被提名人已书面同意作为上 海凯宝药业股份有限公司第六届董事会独立董事候选人。本次提名是在充分了解被提 名人职业、教育背景、专业资格、工作经历、全部兼职等情况后作出的,本提名人认 为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务 规则对独立董事候选人任职资格及独立性的要求,具体声明并承诺如下事项: 一、被提名人已经通过上海凯宝药业股份有限公司第五届董事会提名委员会或者 独立董事专门会议资格审查,提名人与被提名人不存在利害关系或者可能妨碍被提名 人独立履职的其他关系。 √ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任 公司董事的情形。 √ 是 □ 否 如否,请详细说明:______________________________ 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所 业务规则规定的独立董事任职资格和条件。 √ 是 □ 否 如否,请详细说明:___ ...
上海凯宝:独立董事候选人声明与承诺(叶祖光)
2023-12-05 11:11
上海凯宝药业股份有限公司 独立董事候选人声明与承诺 声明人 叶祖光 作为上海凯宝药业股份有限公司第六届董事会独立董事候选 人,现公开声明和保证,本人与该公司之间不存在任何影响本人独立性的关系,且符 合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立董 事候选人任职资格及独立性的要求,具体声明并承诺如下事项: 一、本人已经通过上海凯宝药业股份有限公司第五届董事会提名委员会或者独立 董事专门会议资格审查,提名人与本人不存在利害关系或者可能妨碍本人独立履职的 其他关系。 √ 是 □ 否 如否,请详细说明:______________________________ 如否,请详细说明:______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业务 规则规定的独立董事任职资格和条件。 √ 是 □ 否 如否,请详细说明:______________________________ 四、本人符合该公司章程规定的独立董事任职条件。 √ 是 □ 否 如否,请详细说明:______________________________ 五、本人 ...
上海凯宝(300039) - 2023 Q3 - 季度财报
2023-10-17 16:00
Financial Performance - The company's revenue for Q3 2023 reached ¥307,980,576.42, representing an increase of 18.53% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥60,836,808.13, a significant increase of 69.77% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥60,302,078.04, up 75.27% from the previous year[5] - Total operating revenue for the current period reached ¥1,154,328,501.63, a significant increase from ¥800,013,064.85 in the previous period, representing a growth of approximately 44.3%[20] - Net profit for the current period was ¥195,830,856.66, compared to ¥118,044,013.52 in the previous period, reflecting an increase of approximately 66.1%[21] - Basic and diluted earnings per share increased to ¥0.1875 from ¥0.1134, reflecting a growth of approximately 65.5%[22] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥4,402,537,389.72, reflecting a growth of 3.36% compared to the end of the previous year[5] - Total assets as of September 30, 2023, amounted to CNY 4,402,537,389.72, an increase from CNY 4,259,271,286.92 at the beginning of the year[19] - Total liabilities increased to CNY 580,668,911.42 from CNY 498,240,511.29, reflecting a rise in current liabilities[19] - The total equity attributable to shareholders at the end of Q3 2023 was ¥3,821,549,825.36, a rise of 1.59% from the previous year[5] - The company's total equity as of September 30, 2023, was CNY 3,821,868,478.30, up from CNY 3,761,030,775.63[19] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥289,951,827.18, an increase of 22.70%[5] - Cash flow from operating activities generated a net amount of ¥289,951,827.18, compared to ¥236,316,100.08 in the previous period, an increase of approximately 22.7%[25] - Cash and cash equivalents at the end of the period totaled ¥537,266,310.62, up from ¥261,967,635.68, representing a growth of approximately 105.5%[26] - The company reported a net cash outflow from investing activities of ¥4,405,686.72, compared to a net outflow of ¥197,783,410.48 in the previous period, showing an improvement[25] - The company incurred a total of ¥62,760,000.00 in cash outflows for financing activities, compared to ¥52,300,000.00 in the previous period, representing an increase of approximately 19.1%[25] Research and Development - Research and development expenses increased by 112.59% year-on-year for the first nine months of 2023, indicating a significant investment in innovation[10] - Research and development expenses increased to ¥76,729,257.45 from ¥36,092,230.66, marking a growth of about 112.5%[21] Other Financial Metrics - The company's gross profit margin improved, with operating income for the first nine months of 2023 increasing by 44.29% due to rising market demand[10] - The company reported a 7105.53% increase in credit impairment losses for the first nine months of 2023, attributed to the reversal of bad debt provisions[11] - Total operating costs amounted to ¥927,485,108.17, up from ¥660,043,298.28, indicating a rise of about 40.5%[20] - Total comprehensive income for the current period was ¥122,264,402.67, down from ¥703,354,013.52 in the previous period, indicating a decrease of approximately 82.6%[22] Shareholder Information - The number of common shareholders at the end of the reporting period was 68,852[14] - The top shareholder, Mu Jingwei, holds 16.06% of the shares, totaling 168,029,270 shares[14] Investments - The company has ongoing investments in long-term equity, totaling CNY 7,250,345.66, down from CNY 8,413,013.70[18] - The company reported a significant increase in other receivables, rising to CNY 56,992,863.42 from CNY 35,766,906.83, an increase of approximately 59.5%[18] Audit and Accounting Standards - The third quarter report has not been audited[27] - The new accounting standards were first implemented in 2023, affecting the financial statements from the beginning of the year[27] Corporate Governance - Shanghai Kaibao Pharmaceutical Co., Ltd. held a board meeting on October 17, 2023[28]
上海凯宝:关于公司监事、高级管理人员提前终止减持股份计划的公告
2023-10-16 13:04
证券代码:300039 证券简称:上海凯宝 公告编号:2023-037 上海凯宝药业股份有限公司关于公司 监事、高级管理人员提前终止减持股份计划的公告 公司股东刘绍勇先生、任立旺先生保证向本公司提供的信息内容真实、准确、 完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 上海凯宝药业股份有限公司(以下简称"公司"或"本公司")于 2023 年 4 月 19 日披露了《关于公司监事、高级管理人员减持计划期限届满及未来减持股份计 划预披露的公告》(公告编号:2023-018),公司监事刘绍勇先生(持有公司股份 273,840 股,占公司股份总数的 0.0262%),计划以集中竞价交易方式减持公司股份, 减持数量不超过 68,460 股(占公司股份总数的 0.0065%);公司董事会秘书任立旺 先生(持有公司股份 1,627,192 股,占公司股份总数的 0.1556%),计划以大宗交 易或集中竞价方式减持公司股份,减持数量不超过 406,798 股(占公司股份总数的 0.0389%)。 公司于 2023 年 8 月 16 日披露了《关于公司监事、高级管 ...
上海凯宝:关于使用闲置自有资金购买理财产品的进展公告
2023-10-09 09:13
上海凯宝药业股份有限公司(以下简称"公司"、"上海凯宝")第五届董事 会第十一次会议、2022 年年度股东大会审议通过了《关于使用闲置自有资金进行委 托理财额度的议案》,在保证日常经营运作资金需求、有效控制投资风险的情况下, 同意公司及子公司使用闲置自有资金购买理财产品额度不超过人民币 8 亿元,其年 累计发生额不超过人民币 60 亿元,购买理财产品的额度自股东大会审议通过之日起 12个月内可滚动使用。同时,在上述额度范围内授权管理层具体实施委托理财事宜, 包括但不限于委托理财的形式、期限及金额等。公司独立董事、监事会均发表了同 意的意见。具体内容详见公司于 2023 年 4 月 19 日、2023 年 5 月 12 日在巨潮资讯 网披露的相关公告。 截至本公告日,公司根据经营情况在以上决议授权范围内,使用闲置自有资金 进行银行理财产品、国债逆回购等委托理财事项,现就具体内容公告如下: 一、购买国债逆回购的基本情况 证券代码:300039 证券简称:上海凯宝 公告编号:2023-036 上海凯宝药业股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 ...
上海凯宝:关于公司监事、高级管理人员减持股份时间过半的进展公告
2023-08-16 10:04
证券代码:300039 证券简称:上海凯宝 公告编号:2023-034 上海凯宝药业股份有限公司关于 公司监事、高级管理人员减持股份时间过半的进展公告 公司股东刘绍勇先生、任立旺先生保证向本公司提供的信息内容真实、准确、 完整,没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 上海凯宝药业股份有限公司(以下简称"公司"或"本公司")于 2023 年 4 月 19 日披露了《关于公司监事、高级管理人员减持计划期限届满及未来减持股份计 划预披露的公告》(公告编号:2023-018),公司监事刘绍勇先生(持有公司股份 273,840 股,占公司股份总数的 0.0262%),计划以集中竞价交易方式减持公司股份, 减持数量不超过 68,460 股(占公司股份总数的 0.0065%);公司董事会秘书任立旺 先生(持有公司股份 1,627,192 股,占公司股份总数的 0.1556%),计划以大宗交 易或集中竞价方式减持公司股份,减持数量不超过 406,798 股(占公司股份总数的 0.0389%)。 2023 年 8 月 16 日,公司分别收到刘绍勇先生、任立旺先生 ...
上海凯宝:2023年半年度非经营性资金占用及其他关联资金往来情况汇总表
2023-08-10 09:54
| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2023年期初占 | 2023年度占用 | 2023 年度占 | 2023 年度偿 | 2023 年期末 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 用资金余额 | 累计发生金额 | 用资金的利 | 还累计发生 | 占用资金余 | 因 | | | | | | | | (不含利息) | 息(如有) | 金额 | 额 | | | | 控股股东、实际控制人 | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 其他关联方及附属企 | ...
上海凯宝(300039) - 2023 Q2 - 季度财报
2023-08-08 16:00
Financial Performance - The company's revenue for the first half of 2023 reached ¥846,347,925.21, representing a 56.68% increase compared to ¥540,171,731.25 in the same period last year[20]. - The net profit attributable to shareholders for the reporting period was ¥135,286,640.78, up 63.44% from ¥82,777,022.64 in the previous year[20]. - Basic earnings per share rose to ¥0.1293, a 63.46% increase from ¥0.0791 in the previous year[20]. - The company reported a significant increase in revenue from its main product, the Phlegm-Heat Clearing series, which has established a strong brand presence since its launch[94]. - The total comprehensive income for the period was CNY 239,439,876.43, compared to CNY 191,192,876.91 in the previous period, showing an increase of about 25.3%[189]. Cash Flow and Investments - The net cash flow from operating activities increased by 32.13% to ¥179,156,086.88, compared to ¥135,594,349.20 in the same period last year[20]. - The net increase in cash and cash equivalents was ¥229,601,609.76, a significant rise of 6,348.63%, driven by increased sales and recovered investments[56]. - The cash flow from investing activities was negative at ¥113,205,522.88, a decline of 241.83% due to increased maturity of time deposits[56]. - The company has committed to investing RMB 28,700 million in the "Modernization of Traditional Chinese Medicine and Pharmaceutical Products" project, with 100% completion[76]. - The company has utilized RMB 20,700.00 million for the first phase of the "Modernization of Traditional Chinese Medicine" project[72]. Research and Development - The company has established a joint R&D center with Shanghai Jiao Tong University to enhance collaboration in technology development and product innovation[29]. - The company is committed to R&D investment, with ongoing projects aimed at developing core product series and introducing new products[44]. - Research and development expenses increased to CNY 59,420,486.65, up 138.0% from CNY 24,926,996.65 in the previous year[174]. - The company is focusing on improving its R&D capabilities through various collaborative approaches to mitigate risks associated with new drug development[96]. - The company is advancing the clinical trial of its new product YKRH00020 inhalation solution, which has received a clinical trial notification[44]. Market Strategy and Expansion - The company maintains a comprehensive pharmaceutical business model, focusing on modern traditional Chinese medicine research, production, and sales, with no changes in its main business during the reporting period[28]. - The company’s sales strategy includes a professional academic promotion team to enhance product understanding and market penetration, supported by a comprehensive sales network across various regions[35]. - The company is focusing on market expansion by optimizing channels and exploring new markets, enhancing brand competitiveness[44]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[189]. - The company plans to expand its market presence by launching new products in the second half of 2023[191]. Risk Management and Compliance - The company emphasizes the importance of risk management and has outlined potential risks and countermeasures in the report[3]. - The company is actively managing risks associated with policy changes in the pharmaceutical industry, including stricter regulations and cost control measures[93]. - The company is committed to complying with environmental regulations and standards relevant to its operations[107]. - The company has established an environmental self-monitoring plan in accordance with its discharge permit requirements[114]. - The company has not engaged in high-risk investments such as securities investments in the past twelve months[80]. Corporate Governance and Shareholder Information - The company has maintained a stable management team with no changes in directors or senior management during the reporting period[102]. - The integrity status of the company and its controlling shareholders remains good, with no significant debts due that have not been settled[126]. - The total number of shares held by the top 10 unrestricted shareholders includes significant holdings by Mu Jingwei and Zhang Yanqi, indicating concentrated ownership[152]. - The report does not mention any preferred shares or bond-related situations during the reporting period[159][162]. - The company has not reported any major contracts that would significantly impact its profit during the reporting period[140].
上海凯宝:第五届董事会第十三次会议决议公告
2023-08-08 10:52
证券代码:300039 证券简称:上海凯宝 公告编号:2023-031 上海凯宝药业股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 具体内容详见中国证监会指定的创业板信息披露网站上的相关公告。 表决结果:同意 9 票、反对 0 票、弃权 0 票。 二、审议通过了《2023 年半年度募集资金存放与使用情况的专项报告》的议案 2023 年半年度公司募集资金的存放与使用符合中国证监会、深圳证券交易所关 于上市公司募集资金存放与使用的相关规定,不存在募集资金存放与使用违规的情 形。《2023 年半年度募集资金存放与使用情况的专项报告》已由监事会发表了审核 意见,独立董事就此议案发表了明确同意的意见。 具体内容详见中国证监会指定的创业板信息披露网站上的相关公告。 表决结果:同意 9 票、反对 0 票、弃权 0 票。 特此公告。 上海凯宝药业股份有限公司董事会 上海凯宝药业股份有限公司(以下简称"公司")第五届董事会第十三次会议 通知于 2023 年 7 月 28 日以邮件、书面的方式送达全体董事。会议于 2023 年 8 ...
上海凯宝:第五届监事会第十一次会议决议公告
2023-08-08 10:52
证券代码:300039 证券简称:上海凯宝 公告编号:2023-032 上海凯宝药业股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司(以下简称"公司")第五届监事会第十一次会议通 知于 2023 年 7 月 28 日以邮件方式送达全体监事。会议于 2023 年 8 月 8 日上午在公 司会议室以现场和通讯相结合的方式召开,会议应参会监事三名,实际参会监事三 名。本次会议的召集、召开符合《公司法》、《公司章程》、《公司监事会议事规 则》的有关规定。会议由监事会主席主持,经全体监事审议表决,通过了以下议案: 一、审议通过了《2023 年半年度报告》及《2023 年半年度报告摘要》 经全体监事认真核查认为:《2023 年半年度报告》及《2023 年半年度报告摘要》 的编制和审核程序符合法律、行政法规和中国证监会的规定,报告内容真实、准确、 完整的反映了公司 2023 年半年度经营的实际情况,不存在虚假记载、误导性陈述或 者重大遗漏。 《2023 年半年度报告》及《2023 年半年度报告摘要》详见 ...